Page last updated: 2024-11-05

n-nitrosodibenzylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-Nitrosodibenzylamine (NDBA) is a potent carcinogen that has been classified as a probable human carcinogen by the International Agency for Research on Cancer (IARC). It is a yellow, crystalline solid that is soluble in organic solvents but not in water. NDBA is formed as a byproduct in various industrial processes, including the production of rubber, plastics, and dyes. It has been detected in food, tobacco smoke, and environmental samples. NDBA is of significant research interest because of its carcinogenic potential and its presence in various environmental and industrial settings. Studies have shown that NDBA can induce tumors in a variety of organs, including the liver, esophagus, and stomach. The mechanism of NDBA-induced carcinogenesis is believed to involve the formation of reactive metabolites that damage DNA. Research on NDBA focuses on understanding its formation, its metabolism, its toxicity, and its potential health risks. This research aims to develop strategies for preventing NDBA formation and exposure, as well as to develop effective methods for its detection and analysis.'
```

N-nitrosodibenzylamine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21421
CHEMBL ID166071
SCHEMBL ID3413430
MeSH IDM0064612

Synonyms (35)

Synonym
ccris 2061
dibenzylnitrosamin [german]
benzenemethanamide, n-nitroso-n-(phenylmethyl)-
nsc 338
brn 1842486
n,n-dibenzylnitrosamine
5336-53-8
nsc-338
dibenzylamine, n-nitroso-
dibenzylnitrosamin
nsc338
benzenemethanamine, n-nitroso-n-(phenylmethyl)-
n-nitrosodibenzylamine
dibenzylnitrosamine
wln: onn1r&1r
n,n-dibenzylnitrous amide
n-nitrosodibenzylamine-d4
n-nitroso-n-(phenylmethyl)benzenemethanamine
CHEMBL166071
n,n-dibenzyl-nitrous amide
AKOS024335581
unii-ur93q67p7w
ur93q67p7w ,
3-12-00-02336 (beilstein handbook reference)
FT-0672947
SCHEMBL3413430
1,1-dibenzyl-2-oxohydrazine #
RZJLAUZAMYYGMS-UHFFFAOYSA-N
dibenzylamine n-nitroso-
DTXSID50201520
1,1-dibenzyl-2-oxohydrazine
dibenzyl(nitroso)amine
AS-57854
D93482
EN300-7281779

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" A logistical model was used to further describe the dose-response relationship observed in N-nitrosodibenzylamine-treated liver tissue."( Statistical analysis of lacZ mutant frequency data from MutaMouse mutagenicity assays.
Douglas, GR; Fung, KY; Krewski, D, 1998
)
0.52
" Both L-NAME and/or sapermidine were gavaged to animals in a daily dosage of 10 mg/kg body weight, however, the polyamine was applied for the first 21 days only, and further L-NAME was employed for 3 days (day 22, 23 and 24)."( Nitric oxide synthase inhibitors reduced lipid peroxidation in N-nitrosodiethylamine-treated rats.
Frankiewicz-Jóźko, A; Grudziński, IP, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID226733Carcinogenic potency modelled in silico, (- = non-carcinogen)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (31.25)18.7374
1990's9 (56.25)18.2507
2000's2 (12.50)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.05 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]